Taetle R, Rhyner K, Castagnola J, To D, Mendelsohn J
J Clin Invest. 1985 Mar;75(3):1061-7. doi: 10.1172/JCI111768.
In previous studies, antitransferrin receptor antibody 42/6 inhibited growth of normal granulocyte/macrophage progenitors and some malignant myeloid cells. In these studies, leukemia cell lines cultured without serum and fresh leukemia cells were used to investigate the roles of Fe, transferrin receptors, and transferrin in leukemia cell growth, and mechanisms of 42/6 inhibition and resistance. HL60 and KG-1 leukemia cells grown in serum-free medium were inhibited by 42/6. In contrast to results in fetal calf serum (FCS), soluble Fe (ferric nitriloacetate) reversed 42/6 growth inhibition of serum-free HL60 cells. When HL60 cells were adapted for growth in serum-free, transferrin-free medium, they became refractory to 42/6 growth inhibition. By using radiolabeled transferrin and 42/6, HL60 cells cultured in FCS and transferrin displayed similar quantities of transferrin receptors (29,000-30,000/cell) and similar Kd's (3.8-4.9 X 10(-9) M). Cells grown in transferrin-free medium showed a similar Kd (3.1 X 10(-9) M), but fewer transferrin binding sites (5,000/cell). Transferrin-independent cells contained a log higher concentration of intracellular ferritin. For both FCS and serum-free HL60 cells, calculated affinities for 42/6 were lower (5.7-10.0 X 10(-9) M), but the number of binding sites was three- to fourfold higher. To investigate further the relationship between receptor display and antibody inhibition in proliferating normal and malignant myeloid cells, simultaneous immunofluorescence was used to determine the cell cycle status of transferrin receptor-positive cells. Malignant cells in S + G2/M displayed approximately 50% of the amount of transferrin receptors detected in normal dividing colony-stimulating factor-stimulated marrow cells. Receptor display by dividing cells from two patients with acute nonlymphocytic leukemia was variable. When HL60 cells were exposed to dimethyl sulfoxide, transferrin receptor display decreased, and 42/6 growth inhibition was abrogated or greatly diminished. The presence of 42/6 did not prevent dimethyl sulfoxide-induced HL60 differentiation in serum-containing or serum-free cultures. We conclude that human leukemia cells require Fe for growth and that 42/6 inhibits transferrin-dependent cells by Fe deprivation. Some dividing normal and differentiating malignant cells display reduced transferrin receptors, and can also escape antibody inhibition. The increased ferritin levels and decreased transferrin receptors in transferrin-independent HL60 cells confirm the inverse relationship between cell ferritin content and transferrin receptor display. These studies indicate a critical role for Fe in leukemia cell growth and possible roles in cellular differentiation.
在以往的研究中,抗转铁蛋白受体抗体42/6可抑制正常粒细胞/巨噬细胞祖细胞及某些恶性髓系细胞的生长。在这些研究中,使用无血清培养的白血病细胞系和新鲜白血病细胞来研究铁、转铁蛋白受体及转铁蛋白在白血病细胞生长中的作用,以及42/6抑制作用和耐药的机制。在无血清培养基中生长的HL60和KG-1白血病细胞受到42/6的抑制。与胎牛血清(FCS)中的结果相反,可溶性铁(次氮基三乙酸铁)可逆转42/6对无血清HL60细胞的生长抑制作用。当HL60细胞适应在无血清、无转铁蛋白的培养基中生长时,它们对42/6的生长抑制作用产生耐受。通过使用放射性标记的转铁蛋白和42/6,在FCS和转铁蛋白中培养的HL60细胞显示出相似数量的转铁蛋白受体(29,000 - 30,000/细胞)和相似的解离常数(3.8 - 4.9×10⁻⁹M)。在无转铁蛋白培养基中生长的细胞显示出相似的解离常数(3.1×10⁻⁹M),但转铁蛋白结合位点较少(5,000/细胞)。不依赖转铁蛋白的细胞内铁蛋白浓度高一个对数级。对于FCS和无血清的HL60细胞,计算得出的对42/6的亲和力较低(5.7 - 10.0×10⁻⁹M),但结合位点数量高3至4倍。为了进一步研究正常和恶性增殖性髓系细胞中受体表达与抗体抑制之间的关系,采用同步免疫荧光法来确定转铁蛋白受体阳性细胞的细胞周期状态。处于S + G2/M期的恶性细胞显示出的转铁蛋白受体数量约为正常分裂的集落刺激因子刺激的骨髓细胞中检测到数量的50%。两名急性非淋巴细胞白血病患者的分裂细胞的受体表达情况各不相同。当HL60细胞暴露于二甲基亚砜时,转铁蛋白受体表达下降,42/6的生长抑制作用被消除或大大减弱。在含血清或无血清培养中,42/6的存在并不妨碍二甲基亚砜诱导的HL60分化。我们得出结论,人类白血病细胞生长需要铁,42/6通过剥夺铁来抑制依赖转铁蛋白的细胞。一些正常分裂和分化的恶性细胞显示出转铁蛋白受体减少,并且也能逃避抗体抑制。不依赖转铁蛋白的HL60细胞中铁蛋白水平升高和转铁蛋白受体减少证实了细胞铁蛋白含量与转铁蛋白受体表达之间的反比关系。这些研究表明铁在白血病细胞生长中起关键作用,并可能在细胞分化中发挥作用。